Summary:
Phase 3. This study will evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo for the reduction of the direct transmission rate of influenza A or B from otherwise healthy adults and adolescents to household contacts. Specific objectives and corresponding endpoints for the study are outlined below.
Qualified Participants Must:
• Be between 12 and 64 years of age
•
Have a fever, headache, feverishness or chills, muscle or joint pain, and/or fatigue, soar throat, cough, running nose with in the first 48 hours
Qualified Participants May Receive:
Free Study Medication,
Free Physical Exams,
Compensation per visit